8-K: Journey Medical Secures Major Payer Coverage Expansion for Rosacea Treatment Emrosi

Journey Medical Corporation announced a significant expansion in pharmacy benefit coverage for its recently launched rosacea treatment, Emrosi, now covering 65% of commercial lives in the U.S.

Summary

• Journey Medical Corporation announced that Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules), a treatment for inflammatory lesions of rosacea in adults, now has pharmacy benefit coverage for 65% of the 187 million commercial lives in the United States.
• This represents a substantial increase from 29% commercial lives coverage reported in May 2025.
• The expanded coverage is expected to facilitate further growth in total prescription (TRx) demand for Emrosi.
• Emrosi is available by prescription at specialty pharmacy chains.
• Rosacea is a chronic inflammatory skin condition affecting over 16 million Americans and up to 415 million people worldwide, commonly presenting with facial redness, acne-like lesions, and spider veins.

Sentiment

Score: 9

Explanation: The announcement is overwhelmingly positive, detailing a significant expansion in market access for a key product, which is expected to drive prescription growth and positions the product as a potential standard of care. There are no negative operational or financial outcomes reported.

Positives

• Pharmacy benefit coverage for Emrosi has significantly expanded to 65% of commercial lives in the U.S., up from 29% in May 2025.
• The expanded payer coverage is anticipated to support further growth in total prescription demand for Emrosi.
• The company's targeted contracting strategy, increasing prescription demand, and strong clinical data demonstrating superior efficacy over the current standard of care are driving Emrosi's adoption by commercial payers.
• Emrosi is positioned as a 'best-in-class medicine' and the company believes it will become the standard of care for rosacea treatment.

Risks

• Products and product candidates are subject to time and cost-intensive regulation and clinical testing, and may never be successfully developed or commercialized.
• A substantial portion of sales derive from products that may become subject to third-party generic competition, new competitor products, or an increase in market share of existing competitor products, which could adversely impact operating income.
• Operating in a heavily regulated industry means the impact of future legislation or administrative/executive action is unpredictable.
• Revenue is mainly dependent on dermatology product sales, and any setback could impair operating results.
• Competition, including from manufacturers of generic versions, could limit commercial opportunity and profitability.
• There is a risk that products may not achieve broad market acceptance, including by government and third-party payors.
• Reliance on third parties for several aspects of operations poses a risk.
• The success of the business, including the ability to finance and generate additional revenue, depends on the successful commercialization of Emrosi and any future product candidates.
• Clinical drug development is expensive, time-consuming, and uncertain, and clinical trials may fail to adequately demonstrate safety and efficacy.
• Competitors could develop and commercialize products similar or identical to current offerings.
• Risks related to the protection of intellectual property and the potential inability to maintain sufficient patent protection.
• Business and operations could suffer from computer system failures, cyber-attacks, or deficiencies in cybersecurity.
• There is substantial doubt about the company's ability to continue as a going concern.
• Major public health issues, epidemics, or pandemics could affect product revenues and future clinical trials.
• There is a potential need to raise additional capital.
• Fortress Biotech, Inc. controls a voting majority of common stock, which could be detrimental to other shareholders.

Future Outlook

The company anticipates that the expanded payer coverage will facilitate further growth in total prescription demand for Emrosi. Management looks forward to continuing to expand coverage for Emrosi nationwide and believes the product will become the standard of care for rosacea treatment.

Management Comments

• "We are extremely pleased with the ongoing adoption of Emrosi by commercial payers, which is being driven by our targeted contracting strategy, increasing prescription demand, and strong clinical data demonstrating superior efficacy of Emrosi over the current standard of care."
• "Delivering cost-effective coverage for high-quality dermatologic medicines is a core priority for Journey Medical, and our strong progress with payers and our patient access program both help to ensure that patients receiving a prescription for Emrosi are able to benefit from this best-in-class medicine."
• "We look forward to continuing to expand coverage for Emrosi for patients nationwide, and believe that the product will become the standard of care for the treatment of rosacea."

Industry Context

Rosacea is a widespread chronic inflammatory skin condition affecting millions globally, with significant impact on patients' self-confidence and daily lives. The market for dermatological treatments, particularly for common conditions like rosacea, represents a substantial opportunity for pharmaceutical companies. Journey Medical focuses on FDA-approved prescription products for dermatological conditions, aiming to provide cost-effective, high-quality medicines.

Comparison to Industry Standards

• Emrosi demonstrates superior efficacy over the current standard of care for the treatment of inflammatory lesions of rosacea in adults.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased market access and anticipated growth in prescription demand for a key product, which could lead to improved financial performance.
• Customers (patients): Increased access to Emrosi, a 'best-in-class medicine' for rosacea, potentially improving treatment outcomes and quality of life.
• Payers: Successful contracting strategy indicates effective collaboration with payers to deliver cost-effective coverage.

Next Steps

• Continue to expand coverage for Emrosi for patients nationwide.
• Monitor and facilitate further growth in total prescription demand for Emrosi.

Key Dates

Recommendation

Keywords

Emrosi, rosacea, dermatology, pharmaceutical, payer coverage, prescription drugs, Minocycline Hydrochloride, FDA-approved, commercial lives, skin conditions